Table 1.
Demographic and disease characteristics by age group
| Child-onset n = 297 | Adult-onset n = 6927 | p-value | |
|---|---|---|---|
| Age in years, mean (SD) | 14.0 (2.7) | 43.7 (11.4) | - |
| Female, n (%) | 256 (86%) | 6203 (90%) | 0.07 |
| Race | |||
| White | 162 (55%) | 4296 (62%) | <0.01 |
| Black | 52 (18%) | 1038 (15%) | |
| Hispanic | 38 (13%) | 712 (10%) | |
| Other | 25 (8%) | 218 (3%) | |
| Unknown/Missing | 20 (7%) | 663 (10%) | |
| Region | |||
| Northeast | 34 (11%) | 778 (11%) | 0.68 |
| Midwest | 79 (27%) | 1667 (24%) | |
| West | 48 (16%) | 1017 (15%) | |
| South | 136 (46%) | 3462 (50%) | |
| Unknown/Missing | 0 (0%) | 3 (<1%) | |
| Highest household education | |||
| High school or less | 80 (27%) | 2045 (30%) | 0.60 |
| Bachelor Degree or more | 200 (67%) | 4470 (64%) | |
| Unknown/Missing | 17 (6%) | 412 (6%) | |
| Disease Characteristicsa | |||
| Nephritis | 82 (28%) | 585 (9%) | <0.01 |
| Cerebrovascular disease | 11 (4%) | 626 (9%) | <0.01 |
| Seizure | 29 (10%) | 330 (5%) | <0.01 |
| sychiatric disorder | 63 (21%) | 2099 (30%) | <0.01 |
| aPLS / VTEb | 15 (5%) | 523 (8%) | 0.11 |
| Hospitalization at diagnosisc | 90 (30%) | 763 (11%) | <0.01 |
| Medication Used | |||
| Glucocorticoids, oral | 250 (84%) | 5566 (80%) | 0.10 |
| Cyclophosphamide | 20 (7%) | 145 (2%) | <0.01 |
| Other immunosuppressante | 150 (51%) | 2432 (35%) | <0.01 |
| Mycophenolate | 92 (31%) | 825 (12%) | <0.01 |
| Azathioprine | 47 (16%) | 929 (13%) | 0.23 |
| Methotrexate | 45 (15%) | 1337 (19%) | 0.08 |
| Hydroxychloroquine | 242 (81%) | 5310 (77%) | 0.05 |
a
Disease characteristics assessed within one year of index date
b
Antiphospholipid antibody syndrome or venous thromboembolism
c
Hospitalization within 30 days of first SLE diagnosis code
d
Medication use any time during continuous enrollment
e
Includes mycophenolate, azathioprine, methotrexate, calcineurin inhibitors, and leflunomide